机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital &Guangdong Academy of Medical Sciences, Guangzhou, China广东省人民医院[2]Department ofThoracic Oncological Surgery, Cancer Hospital of University of Chinese Academy ofSciences, Hangzhou, China[3]State Key Laboratory of Respiratory Disease, NationalClinical Research Centre for Respiratory Disease, Guangzhou Institute of RespiratoryHealth, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou,China[4]Second Department of Thoracic Medicine, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University,Changsha, China[5]Department of Respiratory Medicine, The Second Affiliated Hospital, ZheJiang University School Of Medicine, Hangzhou, China[6]Department ofThoracic Surgery, Zhujiang Hospital of Southern Medical University, Guangzhou,China[7]Department of Medical Oncology, Chongqing University Cancer Hospital,Chongqing, China[8]Department of Respiratory Medicine, The First Affiliated Hospitalof Nanchang University, Nanchang, China[9]Department of Medical Oncology, The FirstAffiliated Hospital of Nanchang University, Nanchang, China[10]Department of InternalMedicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan CancerHospital, Zhengzhou, China河南省肿瘤医院[11]Department of Oncology, The Second Affiliated Hospitalof Guangzhou University of Chinese Medicine, Guangzhou, China[12]Department ofThoracic Surgery, Chongqing University Cancer Hospital, Chongqing, China[13]Department of Radiotherapy, Xuzhou Central Hospital, Xuzhou, China[14]Departmentof Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chonqqing, China[15]Department of Medical Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China中山大学附属第一医院[16]Department of Thoracic Surgery,The First Affiliated Hospital, ZheJiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[17]Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The AffiliatedCancer Hospital of Xiangya School of Medicine, Central South University, Changsha,China[18]Department of Oncology, Zhujiang Hospital of Southern Medical University,Guangzhou, China[19]Cancer Center, Cancer Center, Union Hospital, Tongji MedicalCollege, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital &Guangdong Academy of Medical Sciences, Guangzhou, China
推荐引用方式(GB/T 7714)：
C. Xu,Q. Chen,C. Zhou,et al.Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)[J].ANNALS OF ONCOLOGY.2021,32:S1417-S1417.doi:10.1016/j.annonc.2021.10.116.
APA：
C. Xu,Q. Chen,C. Zhou,L. Wu,W. Li...&Y-L. Wu.(2021).Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004).ANNALS OF ONCOLOGY,32,
MLA：
C. Xu,et al."Camrelizumab as neoadjuvant, first- or later-line treatment for non-small cell lung cancer (NSCLC): A retrospective real-world study (CTONG2004)".ANNALS OF ONCOLOGY 32.(2021):S1417-S1417
医学